首页> 外文OA文献 >Late steroid withdrawal after ABO blood group-incompatible living donor kidney transplantation: high rate of mild cellular rejection
【2h】

Late steroid withdrawal after ABO blood group-incompatible living donor kidney transplantation: high rate of mild cellular rejection

机译:ABO血型不相容的活体供体肾移植术后晚期类固醇戒断:轻度细胞排斥反应发生率高

摘要

BACKGROUND: Little is known about the safety of steroid withdrawal after ABO blood group-incompatible living donor kidney transplantation.ududMETHODS: Between September 2005 and November 2007, a total of 15 patients were successfully transplanted over the blood group barrier in our transplantation centers. Similarly to transplant recipients with normal immunological risk, we aimed to taper and eventually stop oral prednisone because of the well-known negative impact of steroids on cardiovascular morbidity and mortality, which in turn is limiting graft survival.ududRESULTS: Up to now, patient and graft survival is 100% after a median follow-up of 839 days (range, 513-1281 days). On the basis of serial protocol biopsies, late steroid withdrawal could successfully be performed in only 5 of 11 patients. Nevertheless, the remaining 6 patients showed histologic signs of mild and subclinical acute rejection shortly after complete withdrawal or even during steroid tapering.ududCONCLUSIONS: With this elevated risk of at least subclinical acute rejection after late steroid withdrawal, we propose that steroid withdrawal in ABO blood group-incompatible kidney graft recipients should only be performed after a protocol biopsy showing normal tissue and together with a thorough clinical and in doubtful cases also histologic follow-up.
机译:背景:关于ABO血型不相容的活体供体肾移植后类固醇戒断的安全性知之甚少。 ud ud方法:2005年9月至2007年11月,在我们的移植中,成功通过血型屏障成功移植了15例患者中心。与具有正常免疫风险的移植受者类似,我们的目标是逐渐减少口服强的松的剂量,并最终停止口服泼尼松,因为众所周知,类固醇对心血管疾病的发病率和死亡率具有负面影响,从而限制了移植物的存活。 ,中位随访839天(范围513-1281天)后,患者和移植物存活率为100%。根据连续方案活检,仅11名患者中的5名可以成功进行晚期类固醇戒断。尽管如此,其余6例患者在完全戒断后甚至在类固醇逐渐减少期间均表现出轻度和亚临床急性排斥的组织学迹象。 ud ud结论:鉴于类固醇晚期撤离后至少具有亚临床急性排斥反应的风险升高,我们建议类固醇戒断在ABO血型不相容的肾移植受者中,仅应在显示正常组织的方案活检后再进行彻底的临床检查,在可疑情况下还应进行组织学随访。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号